Bausch + Lomb Corporation
BLCOHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeBausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and. At a $5.58B market cap, Bausch + Lomb Corporation ranks as a mid-cap company within healthcare. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Market Cap
$5.58B
Beta
0.59
P/E (TTM)
—
P/E (Fwd)
14.72
EPS (TTM)
$-0.62
EPS (Fwd)
$1.08
ROE
-3.3%
ROA
1.4%
Cash
$268.0M
Total Debt
$5.07B
Free CF
$238.5M
52W Change
36.7%
Annual Financials
Cash vs Debt
Bausch + Lomb Corporation carries $5.07B in total debt against $268.0M in cash reserves — debt is roughly 18.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $238.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -3.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.4% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.77B (2022) to $5.10B (2025), reflecting a 35% increase over the period.
BLCO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Bausch + Lomb Corporation's trajectory.